Last reviewed · How we verify
High CBD cannabis
High CBD cannabis is a Small molecule drug developed by Multidisciplinary Association for Psychedelic Studies. It is currently in Phase 2 development. Also known as: Cannabidiol.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | High CBD cannabis |
|---|---|
| Also known as | Cannabidiol |
| Sponsor | Multidisciplinary Association for Psychedelic Studies |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Do Discounted Vouchers for Medical Cannabis Reduce Opioid Use in Adults With Pain (NA)
- Medical Cannabis During Chemoradiation for Head and Neck Cancer
- Cannabis and Polysubstance Use: Response Inhibition and Stress Exposure (PHASE1)
- Repeated CBD Administration and Cannabis Outcomes (EARLY_PHASE1)
- Cannabinoids as a Treatment for Insomnia in Major Depression (PHASE2)
- Pain Inflammation and Cannabis in HIV (NA)
- Tolerability and Efficacy of CBD Extract for RLS Treatment (PHASE2)
- Repeated Administration of Cannabis Varying in THC and CBD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High CBD cannabis CI brief — competitive landscape report
- High CBD cannabis updates RSS · CI watch RSS
- Multidisciplinary Association for Psychedelic Studies portfolio CI
Frequently asked questions about High CBD cannabis
What is High CBD cannabis?
Who makes High CBD cannabis?
Is High CBD cannabis also known as anything else?
What development phase is High CBD cannabis in?
Related
- Manufacturer: Multidisciplinary Association for Psychedelic Studies — full pipeline
- Also known as: Cannabidiol
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing